167 related articles for article (PubMed ID: 30943156)
1. [Nusinersen in SMA children: evolution or revolution? - Clinical use of innovative, repurposed or off-label therapies: a real life experience (2)].
Richelme C
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():22-25. PubMed ID: 30943156
[No Abstract] [Full Text] [Related]
2. [Congenital myasthenic syndromes: repurposing does not simplify access de facto - Clinical use of innovative, repurposed or off-label therapies: a real life experience (4)].
Eymard B
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():28-31. PubMed ID: 30943158
[No Abstract] [Full Text] [Related]
3. [Spinal muscular atrophy treated with nusinersen].
Boesen MS; Albrechtsen S; Born AP
Ugeskr Laeger; 2019 Jan; 181(2):. PubMed ID: 30618374
[TBL] [Abstract][Full Text] [Related]
4. Implementing a Global Expanded Access Program (EAP) for Infantile-Onset Spinal Muscular Atrophy (Type I): Understanding the Imperative, Impact and Challenges.
Yong J; Moffett M; Lucas S
J Neuromuscul Dis; 2019; 6(2):227-231. PubMed ID: 31127730
[TBL] [Abstract][Full Text] [Related]
5. Is There a 'Right to Try' Experimental Therapies? Ethical Criteria for Selecting Patients With Spinal Muscular Atrophy to Receive Nusinersen in an Expanded Access Program.
Jecker NS
Am J Bioeth; 2017 Oct; 17(10):70-71. PubMed ID: 29020544
[No Abstract] [Full Text] [Related]
6. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
[TBL] [Abstract][Full Text] [Related]
7. Nusinersen for SMA: expanded access programme.
Farrar MA; Teoh HL; Carey KA; Cairns A; Forbes R; Herbert K; Holland S; Jones KJ; Menezes MP; Morrison M; Munro K; Villano D; Webster R; Woodcock IR; Yiu EM; Sampaio H; Ryan MM
J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):937-942. PubMed ID: 29549190
[TBL] [Abstract][Full Text] [Related]
8. [Late-onset Pompe disease: the lessons drawn from the use of Myosime
Laforêt P
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():18-21. PubMed ID: 30943155
[No Abstract] [Full Text] [Related]
9. Treatment with Nusinersen - Challenges Regarding the Indication for Children with SMA Type 1.
Pechmann A; Baumann M; Bernert G; Flotats-Bastardas M; Gruber-Sedlmayr U; von der Hagen M; Hasselmann O; Hobbiebrunken E; Horber V; Johannsen J; Kellersmann A; Köhler C; von Moers A; Müller-Felber W; Plecko B; Reihle C; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stoltenburg C; Stüve B; Theophil M; Weiß C; Wiegand G; Wilichowski E; Winter B; Wittmann W; Schara U; Kirschner J
J Neuromuscul Dis; 2020; 7(1):41-46. PubMed ID: 31744015
[TBL] [Abstract][Full Text] [Related]
10. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
[TBL] [Abstract][Full Text] [Related]
11. Nusinersen in spinal muscular atrophy type 1 from neonates to young adult: 1-year data from three Asia-Pacific regions.
Chan SH; Chae JH; Chien YH; Ko TS; Lee JH; Lee YJ; Nam SO; Jong YJ
J Neurol Neurosurg Psychiatry; 2021 Nov; 92(11):1244-1246. PubMed ID: 33574081
[No Abstract] [Full Text] [Related]
12. Effect of Nusinersen on Respiratory Muscle Function in Different Subtypes of Type 1 Spinal Muscular Atrophy.
LoMauro A; Mastella C; Alberti K; Masson R; Aliverti A; Baranello G
Am J Respir Crit Care Med; 2019 Dec; 200(12):1547-1550. PubMed ID: 31433957
[No Abstract] [Full Text] [Related]
13. Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study.
Acsadi G; Crawford TO; Müller-Felber W; Shieh PB; Richardson R; Natarajan N; Castro D; Ramirez-Schrempp D; Gambino G; Sun P; Farwell W
Muscle Nerve; 2021 May; 63(5):668-677. PubMed ID: 33501671
[TBL] [Abstract][Full Text] [Related]
14. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
[TBL] [Abstract][Full Text] [Related]
15. NFL is a marker of treatment response in children with SMA treated with nusinersen.
Olsson B; Alberg L; Cullen NC; Michael E; Wahlgren L; Kroksmark AK; Rostasy K; Blennow K; Zetterberg H; Tulinius M
J Neurol; 2019 Sep; 266(9):2129-2136. PubMed ID: 31123861
[TBL] [Abstract][Full Text] [Related]
16. Nusinersen for Type 1 Spinal Muscular Atrophy: A Father's Perspective.
Hoot NR
Pediatrics; 2019 Oct; 144(4):. PubMed ID: 31506303
[No Abstract] [Full Text] [Related]
17. Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience.
Messina S; Pane M; Sansone V; Bruno C; Catteruccia M; Vita G; Palermo C; Albamonte E; Pedemonte M; Bertini E; Binetti L; Mercuri E;
Neuromuscul Disord; 2017 Dec; 27(12):1084-1086. PubMed ID: 29132728
[No Abstract] [Full Text] [Related]
18. [Accompanying patients in the arrival of new treatments. The AFM-Téléthon regional services experience - Clinical use of innovative, repurposed or off-label therapies: a real life experience (3)].
Merret G
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():26-27. PubMed ID: 30943157
[No Abstract] [Full Text] [Related]
19. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.
Hagenacker T; Wurster CD; Günther R; Schreiber-Katz O; Osmanovic A; Petri S; Weiler M; Ziegler A; Kuttler J; Koch JC; Schneider I; Wunderlich G; Schloss N; Lehmann HC; Cordts I; Deschauer M; Lingor P; Kamm C; Stolte B; Pietruck L; Totzeck A; Kizina K; Mönninghoff C; von Velsen O; Ose C; Reichmann H; Forsting M; Pechmann A; Kirschner J; Ludolph AC; Hermann A; Kleinschnitz C
Lancet Neurol; 2020 Apr; 19(4):317-325. PubMed ID: 32199097
[TBL] [Abstract][Full Text] [Related]
20. Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen.
Winter B; Guenther R; Ludolph AC; Hermann A; Otto M; Wurster CD
J Neurol Neurosurg Psychiatry; 2019 Sep; 90(9):1068-1069. PubMed ID: 30630960
[No Abstract] [Full Text] [Related]
[Next] [New Search]
